CVE:VIV Avivagen (VIV) Stock Price, News & Analysis C$0.0050 0.00 (0.00%) As of 03/5/2024 Add Compare Share Share Stock Analysis Stock Analysis About Avivagen Stock (CVE:VIV) Get Avivagen alerts:Sign Up Key Stats Today's RangeC$0.01▼C$0.0150-Day RangeC$0.01▼C$0.0152-Week RangeC$0.01▼C$0.08Volume2,820 shsAverage Volume49,827 shsMarket CapitalizationC$388.45 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Avivagen Inc. focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr. Tobias dog chews; and Dr. Tobias Beta blend for the human immune system. It serves in Canada, Mexico, Brazil, the Philippines, Taiwan, and Thailand. Avivagen Inc. was incorporated in 2005 and is headquartered in Ottawa, Canada. Read More Receive VIV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avivagen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VIV Stock News HeadlinesAvivagen Inc. (VIVXF) Stock Price, News, Quote & History - Yahoo FinanceMarch 2, 2025 | finance.yahoo.comPure Harvest Corporate Group, Inc. (PHCG)January 3, 2024 | finance.yahoo.comA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the eye-popping yields are fueling a boom among everyday investors. Three years ago, barely a dozen of these funds existed - today there are more than 100, holding over $140 billion. These funds trade on the NYSE and NASDAQ and are built to generate monthly income. Some investors are targeting $5,000 a month with roughly one-tenth of the nest egg Wall Street says you need.October 16 at 1:00 AM | Investors Alley (Ad)Closing Bell: Avivagen Inc flat on Monday (VIV)November 5, 2023 | theglobeandmail.comAvivagen Announces New 500Kg Order for OxC-beta™October 17, 2023 | finance.yahoo.comClosing Bell: Avivagen Inc flat on Friday (VIV)August 25, 2023 | theglobeandmail.comAvivagen Provides Corporate UpdatesJuly 31, 2023 | technews.tmcnet.comClosing Bell: Avivagen Inc up on Friday (VIV)July 29, 2023 | theglobeandmail.comSee More Headlines VIV Stock Analysis - Frequently Asked Questions How have VIV shares performed this year? Avivagen's stock was trading at C$0.01 at the beginning of the year. Since then, VIV stock has increased by 0.0% and is now trading at C$0.01. Industry, Sector and Symbol Stock ExchangeCVE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolCVE:VIV CIKN/A Webwww.avivagen.com Phone613-949-8164FaxN/AEmployees34,000Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$4.64 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-193.44% Debt Debt-to-Equity Ratio2,402.32 Current Ratio0.03 Quick Ratio0.30 Sales & Book Value Annual SalesC$403.78 thousand Price / Sales0.96 Cash FlowC$0.00 per share Price / Cash Flow12.14 Book ValueC($0.12) per share Price / Book-0.04Miscellaneous Outstanding Shares77,690,000Free FloatN/AMarket CapC$388.45 thousand OptionableNot Optionable Beta1.06 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (CVE:VIV) was last updated on 3/5/2024 by MarketBeat.com Staff. From Our PartnersElon Musk’s 4th Wealth Window Set to Open by October 30Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredSpaceX minted 4400 millionaires in a single daySpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...Behind the Markets | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avivagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avivagen With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.